Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $53.71 USD
Change Today -0.78 / -1.44%
Volume 279.7K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

medidata solutions inc (MDSO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/27/15 - $58.97
52 Week Low
10/28/14 - $37.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

medidata solutions inc (MDSO) Related Bloomberg News

View More Bloomberg News

medidata solutions inc (MDSO) Related Businessweek News

No Related Businessweek News Found

medidata solutions inc (MDSO) Details

Medidata Solutions, Inc. provides cloud-based clinical development solutions for life sciences in the United States and internationally. The company offers applications and data analytics for clinical development. It offers Medidata Rave, a platform for capturing, managing, and reporting clinical data; Medidata CTMS, a clinical trial management solution that streamlines operational workflows; Medidata Designer, which enhances the efficiency of clinical trial start-up; Medidata Insights, a clinical business analytics platform; and Medidata Balance, a randomization and trial supply management solution. The company also provides Medidata Patient Cloud application for electronic patient-reported outcome; Medidata Grants Manager, which enables to develop and manage trial budgets; Medidata contract research organization (CRO) Contractor, an analytical tool for CRO outsourcing, budgeting, and negotiation; and Medidata SQM, a set of cloud-based site quality management dashboards. In addition, it offers Medidata Coder that provides medical coding and synonym management solutions; Medidata Safety Gateway, which offers a solution for collecting and transmitting adverse events and related data from the EDC system; and Medidata Targeted SDV that provides auditable and scalable solutions, as well as offers hosting, support, and professional services. Medidata Solutions, Inc. markets and sells its cloud-based solutions through direct sales force, as well as through relationships with CROs and other strategic partners. The company serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and academic institutions, contract research organizations, and other entities engaged in clinical trials. Medidata Solutions, Inc. was founded in 1999 and is headquartered in New York, New York.

1,077 Employees
Last Reported Date: 03/2/15
Founded in 1999

medidata solutions inc (MDSO) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $497.9K
Co-Founder, President, Director and President...
Total Annual Compensation: $497.9K
Chief Operating Officer
Total Annual Compensation: $112.5K
Chief Commercial Officer
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2014.

medidata solutions inc (MDSO) Key Developments

Japanese Biotech JCR Pharmaceuticals Selects Medidata Solutions, Inc.'s Cloud-Based Platform to Power Rare Disease Clinical Research in Japan

Medidata Solutions, Inc. announced that its cloud-based technology platform has been adopted by JCR Pharmaceuticals Co. Ltd. The company is leveraging the Medidata Clinical Cloud® to support research on a therapy for the treatment of Fabry disease, bringing greater speed and operational efficiencies to the organization’s development program in Japan. With a primary focus on biotherapeutics that use recombinant DNA (rDNA) technology to address significant unmet medical needs, JCR Pharmaceuticals is developing therapeutic enzymes to treat lysosomal storage diseases (including Fabry disease), a group of rare genetic diseases that occur in very small patient populations. For its clinical study on a Fabry disease treatment, JCR Pharmaceuticals has selected Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) to streamline clinical trial operations.

Medidata Completes Study Exploring Potential for Instrumenting Patients with Mobile Health Tools in a Clinical Trial Setting

Medidata announced the completion of MOVE-2014, a behavioral study the company sponsored to test whether mobile health (mHealth) devices and tools could be used to drive better health outcomes in overweight adults with Type-2 Diabetes. The pilot open-label clinical trial is part of Medidata’s ongoing efforts to explore the challenges and opportunities associated with the adoption of mobile sensors, wearables and apps in clinical trials - and, in doing so, to enable a new model for drug development that aligns patient needs with faster study execution and reduced costs. MOVE-2014 study participants exhibited high compliance with charging and using the mobile devices, which included wearable activity trackers and smartphones. The study also showed that quantifiable, objective data from the activity trackers and subjective, patient-reported diary data collected via smartphones could be securely pulled into the Medidata Clinical Cloud platform - and seamlessly integrated with other clinical trial information - in a regulatory-compliant manner. Additionally, in assessing the feasibility of using a consumer-grade wearable device to monitor activity among people with Type-2 Diabetes in a real-world setting, MOVE-2014 demonstrated that continuous feedback on exercise and diet regimens could impact patient behavior and, ultimately, health outcomes: more than half of the study participants lost weight. Analysis of the data from MOVE-2014 indicated that subjects were more than 90% compliant with wearing their activity trackers. Medidata’s data science team also identified a number of correlations in the data that could be tested in larger clinical trials, such as a relationship between activity and pain, and a connection between vigorous activity and weight loss. Medidata intends to publish more specific information on MOVE-2014, detailing the protocol development and approval process, as well as how the Company deployed the mHealth devices and trained the MRA doctors and nurses who interacted with study participants. The Company is currently using the technology infrastructure developed for this initiative to enable Phase I-IV mHealth clinical trials for clients worldwide.

Medidata Solutions, Inc. Presents at Jefferies 2015 Global Technology, Media and Telecom Conference, May-13-2015 02:30 PM

Medidata Solutions, Inc. Presents at Jefferies 2015 Global Technology, Media and Telecom Conference, May-13-2015 02:30 PM. Venue: Mandarin Oriental Brickell, Miami, Florida, United States. Speakers: Bryan Charles Spielman, Executive Vice President of Strategy & Corporate Development.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDSO:US $53.71 USD -0.78

MDSO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DATATRAK International Inc $7.10 USD -0.65
Enzo Biochem Inc $2.91 USD -0.04
Luminex Corp $17.16 USD -0.17
OmniComm Systems Inc $0.20 USD 0.00
Oracle Corp $40.36 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation MDSO Industry Range
Price/Earnings 100.0x
Price/Sales 8.3x
Price/Book 10.7x
Price/Cash Flow 373.6x
TEV/Sales 7.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDIDATA SOLUTIONS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at